Neurology · AntiepilepticRegulatory Approvalcommercialmid-term

Aurobindo Pharma's Divalproex Sodium ANDA202419 Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:32:44 AM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Aurobindo Pharma's Divalproex Sodium receiving AP status signals an impending increase in competition within the antiepileptic market. This development necessitates a reassessment of pricing strategies and market positioning for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — DIVALPROEX SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on pricing and market share for existing Divalproex Sodium products. The strongest clinical anchor is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antiepileptic, 8 regulatory and 5 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This AP status indicates Aurobindo is progressing towards market entry, potentially increasing competition in the antiepileptic drug market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIVALPROEX SODIUM (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). While the AP status indicates progress, the final approval and subsequent market launch will be critical in determining compliance and market dynamics.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Aurobindo could lead to price pressures and a potential loss of market share for current Divalproex Sodium products, impacting revenue streams.
Portfolio teams should assess the impact of Aurobindo's entry on pricing and market share for existing Divalproex Sodium products.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval status and any subsequent market launch timelines from Aurobindo.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RISEDRONATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ACP-204 in Adults With Alzheimer's Disease Psychosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Nipocalimab (Imaavy) Approved for Generalised Myasthenia Gravis Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Divalproex Sodium

Commercial impact

medium

The entry of Aurobindo could lead to price pressures and a potential loss of market share for current Divalproex Sodium products, impacting revenue streams.

Regulatory impact

medium

While the AP status indicates progress, the final approval and subsequent market launch will be critical in determining compliance and market dynamics.

What to watch

Monitor the final approval status and any subsequent market launch timelines from Aurobindo.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.